Select a Region North America

EVERSANA’s Direct-to-Patient Care Model Named One of The Most Innovative Strategies of 2022 by PM360

CHICAGO – Dec. 15, 2022 – EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry, today announced that its direct-to-patient care model was named one of the Most Innovative Strategies of 2022 by the leading industry publication PM360.

Developed by combining the power of seven commercialization disciplines including marketing, patient services, specialty pharmacy, data & analytics, market access & reimbursement, field deployment solutions and telehealth, it is the industry’s first and only patient-led virtual care model. The digital end-to-end platform allows patients to choose when and how they meet with a physician, verify benefits in real-time, request prescriptions delivered to their front door and more, all from the comfort of their home.

“Many patients continue to struggle to get the care they need due to a fragmented approach to telehealth, patient engagement, and virtual prescribing across the industry,” said Jim Lang, CEO, EVERSANA. “Our model creates a solution by integrating the power of technology with personalized patient support. It’s a transformative solution to a problem that has impacted patients for far too long. Thanks to PM360 for the recognition and to our team for their efforts to put patients first.”
For more than a decade, the PM360 Innovations Issue, published every December, has served as the industry’s guide to the latest and largest innovations across marketing, commercialization, R&D, and other categories.

Submissions are evaluated by the editorial staff of PM360, and winners across six categories including Companies, Startups, Divisions, Products, Services and Strategies are selected to be featured. This comprehensive overview of the year’s most innovative achievements helps companies in the industry find potential partners and offerings to help advance healthcare efforts around the globe.

The full PM360 Innovation Issue can be found here:

EVERSANA® is a leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit or connect through LinkedIn and Twitter.